Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:17:48.452Z.
Calculation as of: 2026-10-06T16:17:48.452Z.
Quote observation: 2026-10-06T15:53:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fadf2323dc19255bcc42afaef1a50e536e77fb7c46cec045ed2d3efdc7ae0f8f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Moolec Science S.A.
Market Cap
$3.39M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Moolec Science S.A. (MLEC) | $3.39M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.48M | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.28M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.42M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.26M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.55M | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.58M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.59M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.16M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
